MedTrace Logo

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

NCT06235151 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 439

Last updated 2026-04-08

No results posted yet for this study

Summary

This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.

Conditions

Interventions

DRUG

Copper Cu 64 PSMA I&T

Radiopharmaceutical PET imaging tracer injected intravenously for staging of prostate cancer.

Sponsors & Collaborators

  • Curium US LLC

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06235151 on ClinicalTrials.gov